For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
NeuroSense Therapeutics Ltd (NASDAQ: NRSN) closed the day trading at $1.9 down -4.04% from the previous closing price of $1.98. In other words, the price has decreased by -$4.04 from its previous closing price. On the day, 0.57 million shares were traded. NRSN stock price reached its highest trading level at $2.0 during the session, while it also had its lowest trading level at $1.7657.
Ratios:
For a better understanding of NRSN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.21 and its Current Ratio is at 2.21. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.00.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NRSN now has a Market Capitalization of 45578528 and an Enterprise Value of 42273472.
Stock Price History:
The Beta on a monthly basis for NRSN is 1.66, which has changed by 0.7592592 over the last 52 weeks, in comparison to a change of 0.12748289 over the same period for the S&P500. Over the past 52 weeks, NRSN has reached a high of $2.60, while it has fallen to a 52-week low of $0.51. The 50-Day Moving Average of the stock is 23.16%, while the 200-Day Moving Average is calculated to be 53.75%.
Shares Statistics:
Over the past 3-months, NRSN traded about 266.96K shares per day on average, while over the past 10 days, NRSN traded about 371570 shares per day. A total of 23.23M shares are outstanding, with a floating share count of 17.38M. Insiders hold about 27.54% of the company’s shares, while institutions hold 0.81% stake in the company. Shares short for NRSN as of 1749772800 were 394916 with a Short Ratio of 1.48, compared to 1747267200 on 276362. Therefore, it implies a Short% of Shares Outstanding of 394916 and a Short% of Float of 2.0.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of NeuroSense Therapeutics Ltd (NRSN) reflects the combined expertise of 1 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.37, with high estimates of -$0.37 and low estimates of -$0.37.
Analysts are recommending an EPS of between -$0.59 and -$0.59 for the fiscal current year, implying an average EPS of -$0.59. EPS for the following year is -$0.15, with 1.0 analysts recommending between -$0.15 and -$0.15.
